For further information, see: Peer group discussion: improving gout care This is a revision of a previously published article
Regulatory Status BPC 157 is not FDA-approved as a pharmaceutical drug
How We Formulate Our Peptide Blends: Equal Peptide Ratios: Each peptide component is accurately included in equal quantities to achieve the targeted total weight
Why Tirzepatide often outperforms Semaglutide: The additional GIP receptor activity appears to enhance metabolic effects beyond GLP-1 activation alone
It supports tissue repair, inflammation modulation, and regenerative signaling across muscles, tendons, ligaments, and the gut lining, making it a focus for research in angiogenesis research, injury tissue remodelling, and wellness